相关实验视频

Updated: May 7, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

双重定位纳米平台的工程,以提高ROS生成和DSF抗癌活性

Wenqiu Li¹, Haowu Huang¹, Shunyu Yao¹

¹Key Laboratory of Fermentation Engineering (Ministry of Education), Key Laboratory of Industrial Microbiology in Hubei, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), School of Bioengineering and Food, Hubei University of Technology, Wuhan 430068, China. guoguo0302@126.com.

Journal of materials chemistry. B

|June 21, 2024

概括

这项研究开发了结合化学动力学疗法 (CDT) 和化疗 (CT) 的新型纳米粒子,以克服氧化应激和毒性. 这些纳米颗粒有效地向瘤,放大氧化损伤,并增强了协同作用的抗癌效应,提高了安全性.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
在瘤学瘤学.

背景情况:

化学动力学疗法 (CDT) 和化疗 (CT) 面临来自细胞内氧化保护和全身毒性的挑战.
开发能够增强瘤细胞杀伤并最大限度地减少副作用的协同疗法对于癌症治疗至关重要.

研究的目的:

设计和评估用于协同CDT/CT瘤治疗的新型纳米粒子.
为了解决目前CDT的局限性,并减少与传统CT相关的副作用.

主要方法:

开发的含有甲氧化铜 (CP) 和二硫 (DSF) 的3-aminotriazole (3-AT) 杂ZIF-8纳米粒子 (MAF).
功能化纳米颗粒含有氨酸 (HA) 和三素 (TPP) 用于向传递 (CPMDTH).
研究了纳米粒子介导的芬顿类反应,反应性氧物种 (ROS) 放大,以及*in situ*药物复合物的形成.

主要成果:

CPMDTH纳米颗粒通过HA介导的内分细胞和TPP的线粒体向显示了增强的瘤组织积累.
酸性瘤微环境触发了MAF分解,释放了CP,DSF和3-AT,导致放大了OH的产生.
DSF和Cu2+的相互作用形成了细胞毒性Cu (DTC),实现了高效的化疗,具有显著的*in vitro*和*in vivo*抗瘤功效和生物安全性.

结论:

开发的CPMDTH纳米颗粒为协同CDT/CT瘤治疗提供了一个有前途的战略.
这种方法有效地克服了细胞内氧化防御机制,并减少了系统性毒性.
这项研究显示了改善癌症治疗结果的巨大潜力.

更多相关视频

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.